# Tobradex as Intracanal Medicament

> **NCT07332936** · NA · COMPLETED · sponsor: **Umm Al-Qura University** · enrollment: 43 (actual)

## Conditions studied

- Symptomatic Irreversible Pulpitis
- Postoperative Endodontic Pain Following Emergency Root Canal Treatment

## Interventions

- **DRUG:** Calcium Hydroxide (Ca(OH)2)
- **DRUG:** Tobramycin + Dexamethasone

## Key facts

- **NCT ID:** NCT07332936
- **Lead sponsor:** Umm Al-Qura University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07332936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07332936, "Tobradex as Intracanal Medicament". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07332936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*